Clinical trial Recruiting at 2 sites Interventional Ages 18 and up

Low-dose IL-2 after heart attack to study tissue-resident regulatory T cells

Official title: Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells

Run by Cambridge University Hospitals NHS Foundation Trust · NCT07610538 · Data updated 2026-11-12

Researchers are testing whether low-dose interleukin-2 given after a myocardial infarction can boost tissue-resident regulatory T cells to support heart repair.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment24 (estimated)
SponsorCambridge University Hospitals NHS Foundation Trust
Academic / other
Locations2 sites (Cambridge, Cambridgeshire and 1 other locations)
StatusRecruiting
StartedMarch 31, 2026
Main results expectedNovember 1, 2028
Study endsDecember 1, 2028
Registry record updatedMay 28, 2026
Trial IDNCT07610538 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults undergoing CABG who meet the inclusion criteria and do not have the exclusion criteria, particularly without active infection, autoimmune disease, or significant hepatic/kidney disease.

Probably not a fit

Patients with active infection, autoimmune disease, severe organ dysfunction, or those allergic to aldesleukin may not benefit from this treatment.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial investigates the effect of systemic low-dose Aldesleukin (IL-2) on tissue-resident regulatory T cells in patients undergoing CABG after myocardial infarction. Using single-cell and single-nucleus RNA sequencing, the study compares Treg signatures in heart-adjacent tissues to peripheral blood Tregs to see if ld-IL-2 promotes an anti-inflammatory, tissue-repairing phenotype. Participants receive ld-IL-2 alongside standard care, with assessments focused on tissue vasculature and cardiac tissues and their relationship to circulating immune cells. The investigation builds on prior work showing ld-IL-2 effects in blood, aiming to determine whether similar tissue-level effects occur and whether this could translate to improved clinical outcomes such as reduced heart failure.

Why it matters

Potential benefit: If successful, ld-IL-2 could promote tissue repair and reduce heart failure risk after myocardial injury by modulating tissue-resident Tregs.

How similar studies have gone: Prior trials explored ld-IL-2 effects in circulating Tregs; this study extends the question to tissue-resident Tregs, with mixed novelty and some supporting evidence in blood-based studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged over 18 years old
* Undergoing CABG surgery

Exclusion Criteria:

* Critical left main stem coronary disease
* Severe valvular disease (for example 'severe' aortic stenosis as classified on echocardiogram report)
* Haemodynamic instability caused by arrhythmia requiring cardioversion in the current admission
* Non-sustained ventricular tachycardia of \>10 beats in the last 48 hours
* Autoimmune disease
* Any regular immunosuppressive treatment \[Inhaled or topical steroids are permissible\]
* Known active hepatic disease or alanine aminotransferase (ALT) \> 3xULN
* Severe chronic kidney disease (defined as eGFR \< 30 ml/min/1.73m2)
* Allergy or intolerance to aldesleukin
* Signs and symptoms of active infection
* History of human immunodeficiency virus (HIV), hepatitis B or C
* Current malignancy requiring active treatment
* Vaccine within 4 weeks prior to screening
* Women of child-bearing potential and pregnancy (women must be either postmenopausal (defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile (e.g. age appropriate (\>55 years old), history of vasomotor symptoms) or having documented hysterectomy and/or bilateral oophorectomy)
* Women who are breast-feeding
* Clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study

Where it's running

  • Royal Papworth Hospital NHS Foundation Trust
    Cambridge, Cambridgeshire, United Kingdom
    Recruiting
  • Addenbrooke's Hospital
    Cambridge, Cambridgeshire, United Kingdom
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.